MADISON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Wyeth announced today that a jury reached a split verdict after deliberating in two cases in the Court of Common Pleas of the First Judicial District of Pennsylvania. In the first case, Julia Feagins v. Wyeth, the jury rendered a decision in favor of the Company in the damages phase of this bifurcated (two-phase) trial. The verdict ends this case without the need for the second phase of the trial regarding liability.
In the second case, Ida Dupree v. Wyeth, the jury found in favor of plaintiff in the amount of $41,195.12. Wyeth announced that it has waived the second phase of the trial, but will pursue post-trial motions and appellate options, if necessary.
"While the jury made the appropriate decision with regards to Ms. Feagins," says Bob Limbacher, an attorney representing Wyeth, "we do not believe the award for Ms. Dupree is consistent with the evidence presented and we plan to explore our post-trial and appellate options."
The verdicts came at the end of the first phase of a bifurcated (two-phase) trial that began on October 18, 2004 before The Honorable Norman Ackerman. The plaintiffs alleged heart valve injury from the use of the diet drug Pondimin, a drug once marketed by Wyeth.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
CONTACT: Lowell Weiner, +1-973-660-5013, or Justin Victoria,+1-973-660-5340, both of Wyeth; or Douglas Petkus, Wyeth Pharmaceuticals,+1-484-865-5140